Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia

SIMPLE SUMMARY: Acute myeloid leukemia (AML) is a type of blood cancer with an extremely grim prognosis. This is due to the fact that the majority of patients will relapse after frontline treatment. Overall survival of relapsed AML is very low, and treatment options are few. T lymphocytes harnessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Campillo-Davo, Diana, Anguille, Sébastien, Lion, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469736/
https://www.ncbi.nlm.nih.gov/pubmed/34572745
http://dx.doi.org/10.3390/cancers13184519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469736/
https://www.ncbi.nlm.nih.gov/pubmed/34572745
http://dx.doi.org/10.3390/cancers13184519

Ejemplares similares